Despite Cancer Trial Success, Merck (MRK) Stock 39% Under Fair Value
Merck's stock valuation is contentious; Discounted Cash Flow analysis suggests the shares are undervalued, while market multiples indicate a premium. Investors are weighing the company's low value score against an estimate that the stock is materially undervalued.